E-THERAPEUTICS PLC Patent applications |
Patent application number | Title | Published |
20130296437 | Treatment of Depression - There is described a method of treatment of a patient suffering from depression, said method comprising the administration of a sub-analgesic amount of tramadol, or a salt thereof. | 11-07-2013 |
20130053545 | IDENTIFYING COMPONENTS OF A NETWORK HAVING HIGH IMPORTANCE FOR NETWORK INTEGRITY - A computer system ( | 02-28-2013 |
20120284340 | SOCIAL MEDIA ANALYSIS SYSTEM - An information processing apparatus ( | 11-08-2012 |
20120190735 | Cancer Cell Apoptosis - There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent. | 07-26-2012 |
20110257078 | ANTIBACTERIAL COMBINATION THERAPY FOR THE TREATMENT OF GRAM POSITIVE BACTERIAL INFECTIONS - There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof. | 10-20-2011 |
20110191345 | DOCUMENT ANALYSIS SYSTEM - An information processing apparatus ( | 08-04-2011 |
20110039906 | ANTIBACTERIAL COMBINATION THERAPY - There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species. | 02-17-2011 |
20110020217 | TREATMENT OF MELANOMA - There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto. | 01-27-2011 |